GSK's bepirovirsen shows 24% functional cure rate in Chinese subgroup, above 19% global rate

GSK's bepirovirsen achieved an overall functional cure rate of 24% in the Chinese subgroup, higher than the global rate of 19%, with a cure rate of 61% in the favorable-response population. Professor Hou Jinlin, a lead investigator of the global Phase III registration trial, said the results exceeded the team's initial expectations. The article discusses how many steps remain before approval in China.